Navigation Links
Royalty Pharma Statement Regarding Elan Proposal
Date:3/6/2013

o in Royalty Pharma's Proposal;

 "Prothena"

Prothena Corporation plc;

 "SEC"

Securities and Exchange Commission;

 "Specialty Pharma

Companies"

Alkermes plc, Allergan, Inc., Cubist Pharmaceuticals, Inc., Endo Health Solutions 

Inc., Forest Laboratories, Inc., Jazz Pharmaceuticals plc, The Medicines Company,

Salix Pharmaceuticals, Ltd., Shire plc, Valeant Pharmaceuticals International, Inc. and Warner

Chilcott Plc;

 "Tysabri Conference Call"

the February 6, 2013 conference call following the announcement of the Tysabri Transaction;

 "Tysabri Consideration"

the consideration of US$3.249 billion payable by Biogen to Elan Group upon the completion of

the Tysabri Transaction;

 "Tysabri Royalty"

the royalty on Tysabri payable by Biogen to members of the Elan Group following the completion

of the Tysabri Transaction;

 "Tysabri Transaction"

the transaction between Elan and Biogen in relation to the restructuring of Elan's Tysabri collaboration with Biogen which was announced by Elan on February 6, 2013; and

 "Valeant"

Valeant Pharmaceuticals International, Inc. 

APPENDIX II: Chronology of EventsThe following chronology of recent events is provided as further background to the Proposal.

  • September 2011: Sale of Elan Drug Technologies (EDT) to Alkermes plc.
  • Summer 2012: Post-bapineuzumab clinical failure and announcement of spin-off of Prothena, Royalty Pharma developed an interest in Elan and Tysabri.
  • October to December 2012: Royalty Pharma had in-person meeting and several subsequent communications with Elan discussing ways in which Elan and Royalty Pharma might be able to work together, including Royalty Pharma's interest in potentially acquiring Elan.
  • 6 February 2013: Biogen and Elan announced Tysabri Transact
    '/>"/>

  • SOURCE RP Management, LLC
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

    Related biology technology :

    1. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
    2. Cowen Healthcare Royalty Partners Raises $1 Billion
    3. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
    4. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
    5. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
    6. AVANIR Pharmaceuticals To participate in two conferences in March
    7. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
    8. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
    9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
    10. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
    11. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... 24, 2014 The report expects global ... by 2019. It also provides a carefully analyzed data ... challenges for the market. , Full Copy of Report ... the global market for cell expansion will keep witnessing ... expects this growth to be driven by rapid technological ...
    (Date:12/24/2014)... 23, 2014 China Biologic Products, Inc. ... leading fully integrated plasma-based biopharmaceutical company in ... majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., ... the China Food and Drug Administration (the "CFDA") ... previously disclosed in the Company,s public filings, the ...
    (Date:12/24/2014)... , December 23, 2014 ... Algeria , out today and available for free download ... actors driving change and growth in the sector today. ... scored notable successes has been in developing a homegrown pharmaceutical ... percent local production still remains some way off. A cursory ...
    (Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
    Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
    ... Sept. 24 (Nasdaq: MATK ) --,Martek ... into a,multi-year sole source supply agreement with Grupo ... infant formulas produced by Grupo Ricap in,Mexico. Grupo ... and,Martek,s life,sDHA & life,sARA(TM) will initially be available ...
    ... For the ... Bioprocess Industry, ... industry first -- an online interactive design tool that,provides step-by-step ... The GORE(TM) STA-PURE(SM) Bioprocess Configurator is unique to the,bioprocess industry. ...
    ... Corporation,(Nasdaq: NEOG ) announced today that its revenues ... 31, increased 26% from the previous year,s first,quarter to ... year,s $3,011,000 to $3,733,000, or to $0.25 per share ... Neogen,s first quarter revenues, net income, and earnings ...
    Cached Biology Technology:Martek to be the Sole Source Supplier of DHA and ARA for Infant Formulas Produced By Grupo Ricap 2Gore's Legacy of Innovation Extends From Products to Processes 2Gore's Legacy of Innovation Extends From Products to Processes 3Neogen Reports 26% Increase in Revenues 2Neogen Reports 26% Increase in Revenues 3Neogen Reports 26% Increase in Revenues 4Neogen Reports 26% Increase in Revenues 5Neogen Reports 26% Increase in Revenues 6
    (Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
    (Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
    (Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a leader ... million in Series A1 funding led by UK-based Eurovestech. ... participated in the investment round. "We are ... community adopts next-generation sequencing and seeks new approaches for ... Reid Robison , MD MBA, and CEO of Tute ...
    Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
    ... Harvard bioengineer and an MIT aeronautical engineer have created a ... blood sample, potentially allowing doctors to quickly determine whether cancer ... described in the March 17 online edition of the journal ... also detect viruses such as HIV. It could eventually be ...
    ... PhD, has been named the first recipient of the ... Foundation for Eye Research (AFER) to a clinician-scientist under ... and Psychiatry at Stanford University, is being recognized for ... approaches to study neuronal function. "It is ...
    ... -- A nanotechnology-based biosensor being developed by Kansas State ... cells and pathogens, leading to increased food safety and ... chemistry, Hyderabad, India, is developing the biosensor with Jun ... E. coli , but Syed said the same ...
    Cached Biology News:MIT: New blood-testing device can quickly spot cancer cells, HIV 2K-State chemists' biosensor may improve food, water safety and cancer detection 2
    Request Info...
    ... 2D polyacrylamide gel electrophoresis (2D-PAGE) with biological ... core technology platform for proteomic analysis. 2D-PAGE ... samples limited only in the dynamic range ... proteins. Quantitative image based analysis of separated ...
    ... Polymerase is ideal for high-fidelity amplification ... such as cloning and mutagenesis. ... proprietary enzyme preparation containing recombinant DNA ... (3'Cut Site5' exonuclease) activity. Platinum ...
    ... PLAU N-term Antibody This antibody is generated ... synthetic peptide selected within aa 50~150 of ... in PBS with 0.09% (W/V) sodium azide. ... G column and eluted out with both ...
    Biology Products: